决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:CAR-T cell therapy in advanced thyroid cancer: from basic to clinical.
CAR-T 细胞疗法是甲状腺癌一种有前景的治疗手段,我们希望本综述能提供及时且更新的 CAR-T 细胞疗法治疗甲状腺癌研究,以推动该领域发展。
大多数甲状腺癌患者通过以手术为基础的综合治疗可获得良好预后,但晚期甲状腺癌的治疗选择仍有限。嵌合抗原受体修饰T细胞疗法已在肿瘤领域受到广泛关注,并在血液肿瘤中取得显著疗效;然而,多种因素限制了其在甲状腺癌等实体瘤中的效果。本文介绍CAR-T细胞的基本结构和治疗策略,总结针对甲状腺癌相关靶点的临床前研究与临床试验进展,并讨论面临的挑战及可能解决方案。CAR-T疗法是甲状腺癌一种有前景的治疗途径,综述旨在提供及时更新的研究概况,推动该领域发展。
The majority of patients with thyroid cancer can attain a favorable prognosis with a comprehensive treatment program based on surgical treatment. However, the current treatment options for advanced thyroid cancer are still limited. In recent years, chimeric antigen receptor-modified T-cell (CAR-T) therapy has received widespread attention in the field of oncology treatment. It has achieved remarkable results in the treatment of hematologic tumors. However, due to the constraints of multiple factors, the therapeutic efficacy of CAR-T therapy for solid tumors, including thyroid cancer, has not yet met expectations. This review outlines the fundamental structure and treatment strategies of CAR-T cells, provides an overview of the advancements in both preclinical investigations and clinical trials focusing on targets associated with CAR-T cell therapy in treating thyroid cancer, and discusses the challenges and solutions to CAR-T cell therapy for thyroid cancer. In conclusion, CAR-T cell therapy is a promising therapeutic approach for thyroid cancer, and we hope that our review will provide a timely and updated study of CAR-T cell therapy for thyroid cancer to advance the field.
MEMBER ACCOUNT
登录成功会直接打开下一页。